Should We Edit the Genetic Essence of Life?
By Margaret Somerville,
The Globe and Mail
| 06. 08. 2015
Untitled Document
The human germline is the genetic essence of human life. It’s the genes passed on from generation to generation that have evolved over billions of years since the advent of life on Earth which have resulted in each of us. We can now alter an embryo’s germline genes and all descendants of that embryo will inherit those alterations. Is that ethical?
The human germline’s been described as “the common heritage of humankind that must be held in trust for future generations.” Until very recently there was widespread agreement that intentional interference with it was unethical and should not be allowed. The UNESCO Universal Declaration on the Human Genome and Human Rights (1997) characterized germline interventions as “practices that could be contrary to human dignity;” the Council of Europe’s European Convention on Human Rights and Biomedicine (Oviedo Convention, 1997) bans interventions on the human genome that could be inherited, that is, on the human germline; the Canadian Assisted Human Reproduction Act 2004 prohibits “alter[ing] the genome of a cell of a human being or in-vitro embryo such that the...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...